Defendants Seek Dismissal of ‘Extraneous’ Claims in GLP-1 RA Drugs MDL



DOCUMENTS
  • Motion


PHILADELPHIA — Defendants in the MDL for cases alleging injuries caused by glucagon-like peptide-1 receptor agonist drugs such as Ozempic and Mounjaro have moved to dismiss plaintiffs’ claims for breach of warranty, design defect, negligence and medical monitoring.

In a Jan. 24 motion filed before Judge Karen S. Marston of the U.S. District Court for the Eastern District of Pennsylvania, Novo Nordisk and Eli Lilly & Co. argue that the “tacked on” claims “are extraneous to the core issues in the litigation,” inadequately pled, or plainly barred as a matter of law.

GLP-1RAs are a class of drugs used to …






UPCOMING CONFERENCES




HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation Conference

April 08, 2025 - Long Beach, CA
The Westin Long Beach

MORE DETAILS



HarrisMartin's Webinar Series: Fire Litigation Presented by EisnerAmper

March 11, 2025

MORE DETAILS